Stock Groups

Novavax says it could start making Omicron-specific vaccine in January -Breaking

by Mike Robinson

[ad_1]

© Reuters.

(Reuters) – Novavax (NASDAQ:) Inc announced Thursday that it would begin manufacturing a COVID-19 vaccine for Omicron coronavirus variants in January 2019. While it evaluates whether its existing vaccine is effective against it, it will likely start commercial production.

The company expects laboratory (NYSE) data in the coming weeks to show whether antibodies from Novavax patients who had previously been given the COVID-19 shot will neutralize this variant.

Novavax said that it had begun to develop an Omicron-specific spike proteins antigen, and laboratory testing of a vaccine will be conducted within the next few weeks.

Omicron coronavirus has caused a shakeup in markets. There are concerns that it may evade vaccines or prolong the crisis.

Others vaccine producers include Moderna (NASDAQ: Pfizer (NYSE) Have also been working on Omicron-tailored COVID-19 shots.

Novavax’s COVID-19 vaccination was approved in Indonesia for emergency use in November. The Philippines followed suit.

Disclaimer: Fusion MediaThis website does not provide accurate and current data. CFDs are stocks, indexes or futures. The prices of Forex and CFDs are not supplied by exchanges. They are instead provided by market makers. As such, the prices might not reflect market values and could be incorrect. Fusion Media does not accept any liability for trade losses you may incur due to the use of these data.

Fusion MediaFusion Media and anyone associated with it will not assume any responsibility for losses or damages arising from the use of this information, including buy/sell signal data. Trading the financial markets is one of most risky investment options. Please make sure you are fully aware about the costs and risks involved.

[ad_2]